Who is sponsoring NCT05821608?

NCT05821608 is sponsored by Carnegie Mellon University.

What drugs are being tested in NCT05821608?

Interventions in NCT05821608: Message variation 1, Message variation 2.

Is NCT05821608 still recruiting?

NCT05821608 is currently status unknown. Last updated 24 April 2023.

Last reviewed 2023-04-24 · How we verify

NCT05821608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heads up Messages to Increase Call Pick-up Rates

Status unknown NA Last updated 24 April 2023

What this trial tests

NA trial testing Message variation 1 in Various: Health Insurance Members That Could Benefit From Being Connected to a Specialist, e.g., Orthopedic Doctor to Treat Back Pain in 2,000 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
30 June 2023

15 July 2023

Quick facts

Lead sponsor	Carnegie Mellon University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	2,000
Start date	1 May 2023
Primary completion	30 June 2023
Estimated completion	15 July 2023

Drugs / interventions tested

Message variation 1
Message variation 2

Conditions studied

Various: Health Insurance Members That Could Benefit From Being Connected to a Specialist, e.g., Orthopedic Doctor to Treat Back Pain — all drugs for Various: Health Insurance Members That Could Benefit From Being Connected to a Specialist, e.g., Orthopedic Doctor to Treat Back Pain →

Sponsor

Carnegie Mellon University

Who can join

18 and older, any sex, with Various: Health Insurance Members That Could Benefit From Being Connected to a Specialist, e.g., Orthopedic Doctor to Treat Back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to investigate whether notifying health insurance members about an upcoming call can increase their pick-up rates. The study will randomize participants into three groups: control group (no message), treatment group 1 (message variation 1), and treatment group 2 (message variation 2). The primary outcome of interest is the call pick-up rate, and the study will also examine the message opt-out rates for the two different messages.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Carnegie Mellon University trials

Trials by the same sponsor.

NCT07350733 — Cognitive Training for Student Sleep and Wellness · NA · recruiting
NCT06264258 — Game-based Pediatric Diabetes Education · NA · recruiting
NCT06320808 — Evaluating FDA's Proposed Patient Medication Information Handout · NA · completed
NCT05925556 — Pilot Brief Communal Coping Intervention for Adults With Type 1 Diabetes · NA · completed
NCT06459596 — Pilot Brief Communal Coping Intervention for Adults With Type 2 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05821608 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carnegie Mellon University
Last refreshed: 24 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05821608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing